Relief Therapeutics reports positive results for a new treatment option for the rare, painful epidermolysis bullosa.

Relief Therapeutics has announced positive final results from a clinical trial of RLF-TD011 for treating epidermolysis bullosa, a rare skin condition that causes severe blisters and skin fragility. The trial showed promising outcomes, potentially offering a new treatment option for patients suffering from this painful and debilitating disease.

November 11, 2024
9 Articles

Further Reading